<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0864-3466</journal-id>
<journal-title><![CDATA[Revista Cubana de Salud Pública]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Cubana Salud Pública]]></abbrev-journal-title>
<issn>0864-3466</issn>
<publisher>
<publisher-name><![CDATA[Editorial Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0864-34662019000400008</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[El acceso a medicamentos en Latinoamérica, una mirada al caso de Costa Rica]]></article-title>
<article-title xml:lang="en"><![CDATA[Access to medicines in Costa Rica and the rest of Latin America]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Jiménez Herrera]]></surname>
<given-names><![CDATA[Luis]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Costa Rica Facultad de Farmacia ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Costa Rica</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2019</year>
</pub-date>
<volume>45</volume>
<numero>4</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S0864-34662019000400008&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S0864-34662019000400008&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S0864-34662019000400008&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  La Organización Mundial de la Salud recomendó, a los Estados miembros, la implementación de diversas medidas con la intención de garantizar el acceso efectivo y equitativo a los medicamentos, así como su uso racional en armonía con el ambiente. Sin embargo, en Latinoamérica el acceso a los servicios de salud y a los medicamentos tiene una tendencia mercantilista, donde la comercialización se realiza con matices de lucro, lo que transgrede los derechos de las personas que aspiran a un mejor bienestar.  Objetivo:  Describir el acceso a los medicamentos en Latinoamérica particularizando en el caso de Costa Rica.  Métodos:  Este es un trabajo de investigación documental, con enfoque cualitativo, que se basó en la búsqueda y selección de materiales en bases de datos de publicaciones científicas, con el uso de palabras clave. Se organizó la búsqueda en dos secciones: acceso a medicamentos en Latinoamérica y acceso a medicamentos en Costa Rica.  Conclusiones:  Los esfuerzos realizados no son suficientes para lograr el acceso equitativo de los medicamentos, todavía existen diversas causas que generan desigualdades evitables para poder alcanzar los recursos limitados y los medicamentos de mayor costo. Costa Rica, refleja idénticas dificultades que el resto de los países del área. Por lo que debe tener en cuenta los comportamientos desiguales e inadecuados de algunos sectores de la población y trazar estrategias educativas adecuadas para su uso racional, además, de establecer políticas y controles apropiados en contra de los altos precios de los medicamentos.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  The World Health Organization recommended to Member States the implementation of various measures with the intention of ensuring the effective and equitable access to medicines, as well as its rational use in harmony with the environment. However, in Latin America access to health services and medicines has a mercantilist tendency, where marketing is done with nuances of profit which transgresses the rights of people who aspire to an improvement in that regard.  Objective:  To describe the access to medicines in Latin America and, specifically, in Costa Rica.  Methods:  This is a work of documentary research, with a qualitative approach, which was based on the search and selection of materials in databases of scientific publications, with the use of keywords. The search was organized in two sections: access to medicines in Latin America and access to medicines in Costa Rica.  Conclusions:  The efforts made are not enough to achieve the equitable access to medicines. There are still diverse causes that generate avoidable inequalities in order to reach the limited resources and higher cost´s drugs. Costa Rica reflects the same difficulties that the rest of the countries of the area. So, it must be taken into account the unequal and inadequate behaviours of some sectors of the population and create adequate educational strategies for their rational use; and to establish policies and appropriate controls against high prices of medicines.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[acceso]]></kwd>
<kwd lng="es"><![CDATA[medicamentos]]></kwd>
<kwd lng="es"><![CDATA[accesibilidad]]></kwd>
<kwd lng="es"><![CDATA[Latinoamérica]]></kwd>
<kwd lng="es"><![CDATA[precios]]></kwd>
<kwd lng="es"><![CDATA[Costa Rica]]></kwd>
<kwd lng="en"><![CDATA[access]]></kwd>
<kwd lng="en"><![CDATA[medicines]]></kwd>
<kwd lng="en"><![CDATA[accessibility]]></kwd>
<kwd lng="en"><![CDATA[Latin America]]></kwd>
<kwd lng="en"><![CDATA[prices]]></kwd>
<kwd lng="en"><![CDATA[Costa Rica]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<collab>Organización Mundial de la Salud</collab>
<source><![CDATA[El acceso y uso racional de los medicamentos y otras tecnologías sanitarias estratégicos y de alto costo]]></source>
<year>2016</year>
<publisher-loc><![CDATA[Washington ]]></publisher-loc>
<publisher-name><![CDATA[OPS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martins]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Barriers in household access to medicines for chronic conditions in three Latin American countries]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Luiza]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Bastos]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Vialle]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ross]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[Int J Equity in Health]]></source>
<year>2015</year>
<volume>14</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>115-23</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moye]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Policy approaches to improve availability and affordability of medicines in Mexico-an example of a middle income country]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[van Dijk]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Reijneveld]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hogerzeil]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<source><![CDATA[Globalization Health]]></source>
<year>2017</year>
<volume>13</volume>
<numero>53</numero>
<issue>53</issue>
<page-range>1-10</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ramos]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Jóvenes y política: una revisión de estudios desde Latinoamérica]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Apolo]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Jadán]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Observatorio (OBS*)]]></source>
<year>2018</year>
<volume>12</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>169-82</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dos Santos]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical research from the perspective of integrity]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Crippa]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Daron]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Moreira]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Isaia]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Bioética]]></source>
<year>2018</year>
<volume>26</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>172-82</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gaitán]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Decisiones informadas en medicamentos de alto impacto financiero. Un ejemplo de transferencia de conocimiento a nivel regional]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Vaca]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Medicina]]></source>
<year>2018</year>
<volume>40</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>15-24</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ugalde]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Homedes]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<source><![CDATA[Corrupción de la ciencia y violación de derechos humanos-El impacto de las farmacéuticas en los ensayos clínicos realizados en Latinoamérica. Salud colect]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Molyneux]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neglected tropical diseases: progress towards addressing the chronic pandemic]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Savioli]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Engels]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[Lancet]]></source>
<year>2017</year>
<volume>389</volume>
<numero>10066</numero>
<issue>10066</issue>
<page-range>312-25</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gatti]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Apuntes acerca de la industria farmacéutica y sus históricos dilemas éticos]]></article-title>
<source><![CDATA[Dermatol Rev Mex]]></source>
<year>2018</year>
<volume>62</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>81-3</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jiménez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bastías]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Burows]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cerda]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cid]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Fromovich]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<source><![CDATA[Acceso a medicamentos de alto costo y enfermedades de baja frecuencia]]></source>
<year>2012</year>
<publisher-loc><![CDATA[Chile ]]></publisher-loc>
<publisher-name><![CDATA[Pontificia Universidad Católica]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Homedes]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Los retos al acceso y uso adecuado de medicamentos]]></article-title>
<source><![CDATA[História, Ciências, Saúde-Manguinhos]]></source>
<year>2011</year>
<volume>18</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1180-2</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ruiz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Strasser-Weippl]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Youya]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Herrero Vincent]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández-Blanquisett]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[St Louis]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Improving access to high-cost cancer drugs in Latin America: Much to be done]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>2017</year>
<volume>123</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1313-23</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Candia]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Análisis Comparativo sobre la Composición de las Listas Oficiales de Medicamentos de Brasil, Costa Rica y México durante 2010 y 2015]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Sauceda]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Becerril]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Leyva]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Revista Salud y Administración]]></source>
<year>2018</year>
<volume>5</volume>
<numero>14</numero>
<issue>14</issue>
<page-range>19-34</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barrera]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Desarrollo de medicamentos biotecnológicos del laboratorio al paciente]]></article-title>
<source><![CDATA[Rev Med]]></source>
<year>2018</year>
<volume>40</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>44-55</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Homedes]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Ugalde]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[El ciclo de los medicamentos: su impacto en el acceso y el uso adecuado]]></source>
<year></year>
<publisher-name><![CDATA[Salud colect]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dondo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[La equidad en el financiamiento de los medicamentos en Argentina]]></source>
<year>2013</year>
<publisher-loc><![CDATA[Argentina ]]></publisher-loc>
<publisher-name><![CDATA[Universidad Nacional de Quilmes]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chávez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Utilización y gastos en medicamentos convencionales vs tradicional en Ecuador: diferencias entre la población de las cuatro regiones naturales: costa, sierra, amazonía y región insular]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Chancusig]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Horizontes Enferm]]></source>
<year>2018</year>
<volume>7</volume>
<page-range>51-7</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muhammad]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<source><![CDATA[Bitter Pills: The Global War on Counterfeit Drugs]]></source>
<year>2018</year>
<publisher-loc><![CDATA[New York: Oxford ]]></publisher-loc>
<publisher-name><![CDATA[University Press]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bate]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Mathur]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Corruption and Medicine Quality in Latin America: A Pilot Study]]></article-title>
<source><![CDATA[J Econ Analysis Policy]]></source>
<year>2018</year>
<volume>18</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Homedes]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Ugalde]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Ensayos clínicos en América Latina: implicancias para la sustentabilidad y seguridad de los mercados farmacéuticos y el bienestar de los sujetos. Salud colect]]></source>
<year>2016</year>
<volume>12</volume>
<page-range>317-45</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tarín]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incorporation of the new agents in the treatment of multiple myeloma. A challenge in our midst]]></article-title>
<source><![CDATA[Rev Hematol]]></source>
<year>2018</year>
<volume>18</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>151-4</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Medicamentos y transnacionales farmacéuticas: impacto en el acceso a los medicamentos para los países subdesarrollados]]></article-title>
<source><![CDATA[Rev Cubana Farm]]></source>
<year>2010</year>
<volume>45</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>97-110</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lema]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acceso a los medicamentos: las patentes y los medicamentos genéricos: las consecuencias de considerar al medicamento como un bien de mercado y no social]]></article-title>
<source><![CDATA[Rev Bioética Der]]></source>
<year>2015</year>
<volume>34</volume>
<page-range>81-9</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reveiz]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Chapman]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Fitzgerald]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Mendoza]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bolis]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Litigios por derecho a la salud en tres países de América Latina: revisión sistemática de la literatura]]></article-title>
<source><![CDATA[Rev Panam Salud Pública]]></source>
<year>2013</year>
<volume>33</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>213-22</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="confpro">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pinheiro Nunes]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Chaoubah Chaoubah]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Acceso a medicamentos vía judicial en un sistema universal de salud el caso de Brasil]]></source>
<year>2018</year>
<conf-name><![CDATA[ Convención Internacional de Salud Pública Cuba Salud]]></conf-name>
<conf-date>2018 abril 23 - abril 27</conf-date>
<conf-loc>La Habana, Cuba </conf-loc>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Berro]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[How the Uruguayan Judiciary Shapes Access to High-Priced Medicines: A Critique through the Right to Health Lens]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Perehudoff]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Castela]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Health and human rights]]></source>
<year>2018</year>
<volume>20</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>93-8</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Beláustegui]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<source><![CDATA[Las compras públicas sustentables en América Latina. Estado de avance y elementos clave para su desarrollo]]></source>
<year>2011</year>
<publisher-loc><![CDATA[Ecuador ]]></publisher-loc>
<publisher-name><![CDATA[Universidad Nacional de San Martín]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Álvarez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Análisis Comparativo de Precios de Medicamentos en América Latina]]></source>
<year>2018</year>
<publisher-loc><![CDATA[Chile ]]></publisher-loc>
<publisher-name><![CDATA[Universidad de Chile]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alvarenga]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Peña]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Política social inclusiva y servicios privados de salud en Costa Rica: encuentros, desencuentros y retos]]></source>
<year>2018</year>
<publisher-loc><![CDATA[Costa Rica ]]></publisher-loc>
<publisher-name><![CDATA[Universidad de Costa Rica]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Román]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<source><![CDATA[Social protection systems in Latin America and the Caribbean: Costa Rica]]></source>
<year>2012</year>
<publisher-loc><![CDATA[Chile ]]></publisher-loc>
<publisher-name><![CDATA[United Nations]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jiménez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[La política nacional de medicamentos en el contexto de América Latina]]></article-title>
<source><![CDATA[Rev Cub Sal Públ]]></source>
<year>2018</year>
<volume>44</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>1-22</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="book">
<collab>Organización Mundial de la Salud</collab>
<source><![CDATA[Política de Medicamentos de Centroamérica y República Dominicana]]></source>
<year>2014</year>
<publisher-loc><![CDATA[Guatemala ]]></publisher-loc>
<publisher-name><![CDATA[Sector Salud de Centroamérica y República Dominicana]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="book">
<collab>Organización Mundial de la Salud</collab>
<collab>Organización Panamericana de la Salud</collab>
<source><![CDATA[Agenda salud sostenible para las Américas 2018-2030]]></source>
<year>2017</year>
<publisher-loc><![CDATA[USA ]]></publisher-loc>
<publisher-name><![CDATA[160a Sesión Comité Ejecutivo]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Porras]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Vargas]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Diagnóstico del mercado de medicamentos]]></source>
<year>2015</year>
<publisher-loc><![CDATA[Costa Rica ]]></publisher-loc>
<publisher-name><![CDATA[Ministerio de Economía, Industria y Comercio de Costa Rica]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muiser]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Institutionalization of Universal Health Policy in Costa Rica and Current Challenges]]></article-title>
<source><![CDATA[Rev. costarric. salud pública]]></source>
<year>2013</year>
<volume>22</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>94-103</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="book">
<collab>Oficina Comercial de ProChile</collab>
<source><![CDATA[Estudio de mercado de medicamentos en Costa Rica]]></source>
<year>2011</year>
<publisher-loc><![CDATA[Costa Rica ]]></publisher-loc>
<publisher-name><![CDATA[ProChile]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Revisiting Health Rights Litigation and Access to Medications in Costa Rica: Preliminary Evidence from the Cochrane Collaboration Reform]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Morales]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Norheim]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Wilson]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<source><![CDATA[Health and human rights]]></source>
<year>2018</year>
<volume>20</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>79</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ajún]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<source><![CDATA[Estrategia de mercadeo para la comercialización de productos naturales en una empresa farmacéutica de venta al detalle]]></source>
<year>2013</year>
<publisher-loc><![CDATA[Costa Rica ]]></publisher-loc>
<publisher-name><![CDATA[Universidad de Costa Rica]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="book">
<collab>Proexport Colombia</collab>
<source><![CDATA[Estudio de mercado Costa Rica. Sector farmacéutico]]></source>
<year>2004</year>
<publisher-loc><![CDATA[Colombia ]]></publisher-loc>
<publisher-name><![CDATA[Programa de información al exportador por Internet]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="book">
<collab>Comisión Económica para América Latina y el Caribe</collab>
<source><![CDATA[Estudio Económico de América Latina y el Caribe 2016: La Agenda 2030 para el Desarrollo Sostenible y los desafíos del financiamiento para el desarrollo]]></source>
<year>2016</year>
<publisher-loc><![CDATA[Chile ]]></publisher-loc>
<publisher-name><![CDATA[CEPAL]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fallas Villalobos]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Mercado de farmacias en Costa Rica aún tiene espacio para más competidores]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Petrecolla]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[Condiciones de competencia en el sector de los medicamentos de Centroamérica y Panamá]]></source>
<year>2011</year>
<publisher-loc><![CDATA[Costa Rica ]]></publisher-loc>
<publisher-name><![CDATA[Banco Interamericano de Desarrollo]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Román]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Judicialización de la salud: revisión de los recursos de amparo relacionados con medicamentos, 2006-2013]]></source>
<year>2014</year>
<publisher-loc><![CDATA[Costa Rica ]]></publisher-loc>
<publisher-name><![CDATA[Programa Estado de la Nación]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Segura]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Medicamentos genéricos: su importancia económica en los sistemas públicos de salud y la necesidad de estudios in vitro para establecer su bioequivalencia]]></article-title>
<source><![CDATA[Rev. Pensamiento Actual]]></source>
<year>2017</year>
<volume>17</volume>
<numero>28</numero>
<issue>28</issue>
<page-range>108-20</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barrantes]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Coberturas de atención de servicios de salud de primer nivel en la Caja Costarricense de Seguro Social en los años 2014 y 2015 por área de salud: análisis de situación, brechas de acceso y construcción de un índice]]></source>
<year>2017</year>
<publisher-loc><![CDATA[España ]]></publisher-loc>
<publisher-name><![CDATA[Universidad de Alcalá]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[La doble cara de la reforma del sector salud en Costa Rica en la década del noventa. Realidad]]></article-title>
<source><![CDATA[Rev. Cienc. Soc. Hum.]]></source>
<year>2017</year>
<volume>119</volume>
<page-range>131-67</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="book">
<collab>Asamblea Legislativa de Costa Rica</collab>
<source><![CDATA[Control de precios de los medicamentos Proyecto de Ley 17.738]]></source>
<year>2010</year>
<publisher-loc><![CDATA[Costa Rica ]]></publisher-loc>
<publisher-name><![CDATA[Departamento de servicios parlamentarios]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cont]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Panadeiros]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Urbiztondo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Acuerdo de Comercio Mercosur-Unión Europea: impacto sobre el gasto en medicamentos adquiridos en farmacias y por PAMI en Argentina]]></source>
<year>2018</year>
<publisher-loc><![CDATA[Argentina ]]></publisher-loc>
<publisher-name><![CDATA[Fundación de investigaciones económicas latinoamericanas]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jiménez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Medicamentos subutilizados en el ámbito comunitario, Área Salud Coronado, CR]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Blanco]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev. costarric. salud pública]]></source>
<year>2006</year>
<volume>15</volume>
<numero>28</numero>
<issue>28</issue>
<page-range>50-61</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vidal]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Judicialización y acceso a tecnologías sanitarias: oportunidades y riesgos]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Fabio]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev. Panam Salud Pública]]></source>
<year>2017</year>
<volume>41</volume>
<page-range>1-5</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>51</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Islas]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[América Latina. La democracia obstruida]]></article-title>
<source><![CDATA[Revista Internacional de Comunicación y Desarrollo (RICD)]]></source>
<year>2018</year>
<volume>2</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>3-28</page-range></nlm-citation>
</ref>
<ref id="B52">
<label>52</label><nlm-citation citation-type="book">
<collab>Asamblea Legislativa de Costa Rica</collab>
<source><![CDATA[Fortalecimiento de las finanzas públicas]]></source>
<year>2018</year>
<publisher-loc><![CDATA[Costa Rica ]]></publisher-loc>
<publisher-name><![CDATA[Asamblea Legislativa de Costa Rica]]></publisher-name>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
